Advantx Pharmaceuticals
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
141 W 53rd St, New York City, New York, ...Website
www.advantx.orgRevenue
$20.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Advantx Pharmaceuticals
Headquartered in New York and founded in 2022 by the Advantx Foundation, Advantx Pharmaceuticals Inc. is a biopharmaceutical company focused on bringing to market innovative therapies for central nervous system diseases based on Sigma receptors, unique ligand-operated chaperone proteins key regulators of the human body. REVOLUTIONIZING THE TREATMENT OF RARE AND CHRONIC CONDITIONS WITH INNOVATIVE SIGMA-TARGETED THERAPIES Unique Platform Targeting Sigma: Advantx Pharmaceuticals leads the global biotech industry with a proprietary Sigma platform of pharmaceutical-grade compounds that selectively target and modulate the ligand-operated chaperone proteins encoded by the SIGMAR1 and SIGMAR2 genes. Unlocking the Potential of Sigma Proteins: Sigma proteins, a unique evolutionary isolate distinct from any other human proteins, represent the pinnacle of protein evolution. As the unique ligand-operated chaperone receptor proteins, they play a crucial role in the intricate workings of the company'Read more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Advantx Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Advantx Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Advantx Pharmaceuticals
Check if Advantx Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Advantx Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Advantx Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Advantx Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Advantx Pharmaceuticals is spiking on competitors!
Click to see if Advantx Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Advantx Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Advantx Pharmaceuticals
Compare insights from companies similar to Advantx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Advantx Pharmaceuticals
$20.7M
51-200
Private
-
2022
N/A
Company Profile Activity
Activity Insights
Advantx Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Advantx Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Advantx Pharmaceuticals.
Advantx Pharmaceuticals Tech Stack
A closer look at the technologies used by Advantx Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Advantx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Headquartered in New York and founded in 2022 by the Advantx Foundation, Advantx Pharmaceuticals Inc. is a biopharmaceutical company focused on bringing to market innovative therapies for central nervous system diseases based on Sigma receptors, unique ligand-operated chaperone proteins key regulators of the human body. REVOLUTIONIZING THE TREATMEN... Read More
